STTK
NASDAQShattuck Labs Inc.
News · 26 weeks47+20%
2025-12-142026-06-07
Mix2490d
- Insider14(58%)
- SEC Filings6(25%)
- Other3(13%)
- Analyst1(4%)
Latest news
25 items- PRShattuck Labs Announces Phase 1 Results for SL-325Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1 mg/kg and higherWell tolerated with a favorable safety profile consistent with the TL1A inhibitor classNo evidence of DR3 agonismRECEPTIVE-CD1 Phase 2b clinical trial in patients with Crohn's disease expected to initiate in the third quarter of 2026 Lead bispecific product candidate, SL-846 (DR3xIL-23R), currently being evaluated in IND-enabling toxicology studies; Phase 1 initiation expected in the first half of 2027 AUSTIN, TX and DURHAM, NC, June 08, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, I
- PRShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it will host an investor call and webcast on Monday, June 8, 2026 at 8:00 a.m. ET to present comprehensive Phase 1 clinical data for SL-325, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic and immunogenicity results and provide a pipeline update. The event will feature presentations by members of Shat
- INSIDERSEC Form 4 filed by Director Golumbeski George4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Ashiya Mona4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Baker Daniel G.4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Siegall Clay B4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Gibson Neil W4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Boudreau Helen M4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- SECSEC Form 8-K filed by Shattuck Labs Inc.8-K - Shattuck Labs, Inc. (0001680367) (Filer)
- INSIDERDirector Siegall Clay B was granted 128,054 shares, increasing direct ownership by 100% to 256,108 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERChief Technical Officer Shukla Abhinav A. was granted 5,122 shares, increasing direct ownership by 6% to 86,380 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDEROfficer Stout Stephen was granted 12,805 shares, increasing direct ownership by 16% to 93,366 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERChief Financial Officer Neill Andrew R was granted 64,027 shares, increasing direct ownership by 28% to 292,251 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERChief Technical Officer Shukla Abhinav A. exercised 2,032 shares at a strike of $3.57 and sold $14,244 worth of shares (2,032 units at $7.01) as part of a pre-agreed trading plan (SEC Form 4) to cover taxes4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERChief Medical Officer Pandite Arundathy N. sold $198,300 worth of shares (30,000 units at $6.61) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 166,219 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERChief Executive Officer Schreiber Taylor was granted 25,610 shares, increasing direct ownership by 27% to 122,222 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDEROfficer Stout Stephen covered exercise/tax liability with 968 shares, decreasing direct ownership by 1% to 80,561 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- SECSEC Form 144 filed by Shattuck Labs Inc.144 - Shattuck Labs, Inc. (0001680367) (Subject)
- SECSEC Form 10-Q filed by Shattuck Labs Inc.10-Q - Shattuck Labs, Inc. (0001680367) (Filer)
- SECShattuck Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Shattuck Labs, Inc. (0001680367) (Filer)
- PRShattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsPhase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter of 2026 – AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2026 and provided recent business highlights. "We are pl
- ANALYSTCantor Fitzgerald initiated coverage on Shattuck LabsCantor Fitzgerald initiated coverage of Shattuck Labs with a rating of Overweight
- SECSEC Form DEFA14A filed by Shattuck Labs Inc.DEFA14A - Shattuck Labs, Inc. (0001680367) (Filer)
- SECSEC Form DEF 14A filed by Shattuck Labs Inc.DEF 14A - Shattuck Labs, Inc. (0001680367) (Filer)
- ANALYSTNeedham resumed coverage on Shattuck Labs with a new price targetNeedham resumed coverage of Shattuck Labs with a rating of Buy and set a new price target of $25.00
STTK FAQ
7 questionsWhat does Shattuck Labs Inc. do?
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.Where does STTK stock trade?
Shattuck Labs Inc. (STTK) is listed on NASDAQ.What sector and industry is STTK in?
Shattuck Labs Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Shattuck Labs Inc. go public?
Shattuck Labs Inc. (STTK) completed its IPO in 2020.What are analysts saying about STTK?
Shattuck Labs Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-04-27.What companies are similar to STTK?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare STTK side-by-side with any of them on Quantisnow.How can I track STTK on Quantisnow?
Quantisnow aggregates Shattuck Labs Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STTK to receive live email and push alerts on every new disclosure.